摘要
Elevatedheartrateisamajorriskfactorforcardiovasculardiseases.Theinhibitoroffunnycurrent(I(f)),ahyperpolarization-activatedcyclicnucleotide-gatedchannelcurrent,ivabradineisanewagentselectivelyreducingheartratedevoidofothercardiovasculareffects,whichhascomeintothemarketinEuropeformorethan3years.Ithasbeenapprovedthatpureheartratereductionbyivabradinecanimprovemyocardialischemia,endothelialfunctionandmyocardialcontractilefunction.Long-termadministrationwillnotincreaseall-causemortality.Itstherapeuticvalueinstablecoronaryarterydiseasehasbeenverifiedinclinicalpractice,whileinotherfieldsofcardiovasculardiseasesstillneedsmoreevidence-basedmedicalresearch.Thisarticleisareviewaboutitsrecentresearchadvancesinexperimentalandclinicalstudies.
出版日期
2009年02月12日（中国期刊网平台首次上网日期，不代表论文的发表时间）
